Clinical Drug Experience Knowledgebase

acalabrutinib (calquence) (3 trials)

bendamustine (treanda) (12 trials)

chlorambucil (Leukeran) (5 trials)

cyclophosphamide (cytoxan) (14 trials)

darbepoetin alfa (aranesp) (1 trial)

fludarabine (fludara) (17 trials)

ibrutinib (imbruvica) (6 trials)

lenalidomide (revlimid) (2 trials)

mitoxantrone (novantrone) (4 trials)

obinutuzumab (gazyva) (17 trials)

rituximab (rituxan) (12 trials)

sargramostim (leukine) (4 trials)

venetoclax (venclexta) (8 trials)

alemtuzumab (campath) (8 trials)

allogeneic lymphocytes (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

autologous bone marrow (1 trial)

busulfan (myleran) (1 trial)

carmustine (bicnu) (2 trials)

cyclosporine (sandimmune) (1 trial)

cytarabine (cytosar-u) (2 trials)

doxorubicin (Doxil) (1 trial)

eltrombopag (promacta) (1 trial)

entospletinib (1 trial)

etoposide (vepesid) (2 trials)

idelalisib (zydelig) (2 trials)

melphalan (alkeran) (2 trials)

mycophenolate (myfortic) (1 trial)

naltrexone (revia) (2 trials)

ofatumumab (arzerra) (1 trial)

peripheral blood hematopoietic cell (3 trials)

prednisone (meticorten) (1 trial)

sitravatinib (1 trial)

tirabrutinib (2 trials)

tislelizumab (1 trial)

urea (2 trials)

vincristine (oncovin) (1 trial)

zanubrutinib (Brukinsa) (2 trials)